While both drugs are effective, some studies suggest that tirzepatide may offer greater weight loss benefits compared to semaglutide
Beyond that landmark study, the evidence base includes research showing GHK-Cu enlarges hair follicle size, extends the anagen (active growth) phase, stimulates dermal papilla cells (the cells that control follicle activity), promotes angiogenesis (blood vessel growth) to the scalp, and reduces the DHT-related inflammation that causes follicle miniaturization in androgenetic alopecia
A 2024 safety review in ScienceDirect noted that tirzepatide may have slightly better GI tolerability than semaglutide, likely because of its dual mechanism ( ScienceDirect , 2024)
These GLP-1 receptor agonists are increasingly prescribed for obesity and weight management, helping many people reduce appetite, regulate blood sugar and lose significant weight over time
Unfortunately, in this disease state, there's a lot of perceived stigmas, and so it allows patients to do this from the anonymity of their home, while still getting the absolute best cash price in the market if they don't have commercial coverage. Approved by the FDA in 2021, semaglutide became the first weekly GLP-1 RA specifically indicated for chronic weight management, marking a major shift in how health care professionals treat obesity